Sanofi Accelerates Scientific Presence With Opening Of Global R&D Operations

Sanofi’s new R&D operations hub confirms China as the third pillar of Sanofi Global Clinical Sciences and Operations, joining facilities in France and the United States.

With an investment of €66 million ($78 million), the Hub will support the clinical research and development of Sanofi’s innovative drugs by focusing on the management of global multi-center clinical trials data and files. Bringing together global data and analysis, the Hub will accelerate the availability of trial results, from Phase I to Phase IV. The Hub will take advantage of local talents to further strengthen Sanofi’s digital capabilities.

“Through this new Hub, we will take full advantage of our global experience and R&D capabilities together with local scientific research strengths to further improve innovation,” said Zhang Ji, Ph.D., senior VP, global head of Sanofi R&D operations. “Our goal is to link China’s innovative achievements with the global ecosystem and develop innovative drugs in China that could benefit patients around the world.”

The Chengdu Hub will target diseases that affect millions of people across our therapeutic areas: diabetes and cardiovascular diseases, vaccines, oncology, immunology and inflammation, rare diseases, multiple sclerosis, and neurology. It will leverage global cutting-edge biological technology for polypeptides, gene therapy, monoclonal antibodies, and multi-specific antibodies. The Hub plans to recruit 300 local pharmaceutical research and development professionals by 2020.

(Source and Feature Image: Sanofi)